The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes
2019 ◽
Vol 157
◽
pp. 107893
◽
Keyword(s):
Keyword(s):
Keyword(s):